{"id":"interferon-alfa-fluorouracil","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL2108506","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Interferon alfa activates the JAK-STAT pathway, which increases the expression of genes involved in antiviral defense and immune modulation. Fluorouracil's inhibition of thymidylate synthase leads to a depletion of thymidine triphosphate, essential for DNA replication, thereby inducing apoptosis in cancer cells.","oneSentence":"Interferon alfa binds to interferon receptors on the surface of cells, leading to the activation of JAK-STAT signaling pathways which enhance antiviral and antiproliferative responses; Fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis and repair in rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:37:06.964Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma"}]},"trialDetails":[{"nctId":"NCT04380545","phase":"PHASE1, PHASE2","title":"Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-13","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8","enrollment":15},{"nctId":"NCT00019474","phase":"PHASE2","title":"Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"1998-03","conditions":"Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor","enrollment":60},{"nctId":"NCT01834963","phase":"PHASE2","title":"P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma.","status":"UNKNOWN","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2013-03","conditions":"Hepatocellular Carcinoma","enrollment":66},{"nctId":"NCT00262951","phase":"PHASE2","title":"Chemoradiation in Locally Advanced Pancreatic Cancer","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-01","conditions":"Pancreatic Cancer","enrollment":23},{"nctId":"NCT00059826","phase":"PHASE2","title":"Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2003-03","conditions":"Pancreatic Cancer","enrollment":89},{"nctId":"NCT02068131","phase":"PHASE2","title":"Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"The Affiliated Hospital of the Chinese Academy of Military Medical Sciences","startDate":"2014-02","conditions":"Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT00524498","phase":"PHASE2","title":"A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2007-09","conditions":"Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT00053820","phase":"PHASE3","title":"Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"2002-07","conditions":"Kidney Cancer","enrollment":670},{"nctId":"NCT00003585","phase":"PHASE1, PHASE2","title":"Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"1996-08","conditions":"Kidney Cancer","enrollment":35},{"nctId":"NCT00003664","phase":"PHASE2","title":"Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically","status":"UNKNOWN","sponsor":"Cancer Biotherapy Research Group","startDate":"1998-10","conditions":"Kidney Cancer","enrollment":30},{"nctId":"NCT00016042","phase":"PHASE1","title":"Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer","status":"UNKNOWN","sponsor":"St. Luke's Medical Center","startDate":"2001-01","conditions":"Colorectal Cancer, Kidney Cancer","enrollment":""},{"nctId":"NCT00003063","phase":"PHASE3","title":"Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer","status":"UNKNOWN","sponsor":"European Institute of Oncology","startDate":"1991-11","conditions":"Colorectal Cancer","enrollment":1050},{"nctId":"NCT00030342","phase":"PHASE1, PHASE2","title":"Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer","status":"COMPLETED","sponsor":"St. Luke's Medical Center","startDate":"2001-11","conditions":"Colorectal Cancer, Kidney Cancer","enrollment":60},{"nctId":"NCT00003172","phase":"PHASE2","title":"Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-12","conditions":"Gastric Cancer","enrollment":""},{"nctId":"NCT00002470","phase":"PHASE2","title":"Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors","status":"COMPLETED","sponsor":"Mid-Atlantic Oncology Program","startDate":"1990-09","conditions":"Gastrointestinal Carcinoid Tumor, Lung Cancer","enrollment":""},{"nctId":"NCT00660270","phase":"PHASE2","title":"Chemotherapy and Radiation Following Pancreatic Surgery","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2002-05","conditions":"Pancreatic Cancer","enrollment":53},{"nctId":"NCT00227656","phase":"PHASE2","title":"Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-09","conditions":"Breast Cancer, Metastatic Cancer","enrollment":2},{"nctId":"NCT00053807","phase":"PHASE3","title":"Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-02","conditions":"Kidney Cancer","enrollment":96},{"nctId":"NCT00004897","phase":"PHASE2","title":"Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer","status":"TERMINATED","sponsor":"Northwestern University","startDate":"1999-10","conditions":"Esophageal Cancer","enrollment":""},{"nctId":"NCT00311467","phase":"PHASE3","title":"Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma","status":"TERMINATED","sponsor":"Central European Cooperative Oncology Group","startDate":"2004-03","conditions":"Renal Cell Cancer","enrollment":172},{"nctId":"NCT00068575","phase":"PHASE2","title":"Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-05","conditions":"Pancreatic Cancer","enrollment":29},{"nctId":"NCT00277017","phase":"PHASE1, PHASE2","title":"Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma","status":"COMPLETED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2000-09","conditions":"Kidney, Cancer","enrollment":15},{"nctId":"NCT00761241","phase":"PHASE2","title":"Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT","status":"COMPLETED","sponsor":"Benaroya Research Institute","startDate":"2008-09","conditions":"Pancreatic Cancer","enrollment":40},{"nctId":"NCT00178802","phase":"PHASE2","title":"Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers","status":"UNKNOWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"1996-06","conditions":"Breast Neoplasms, Endometrial Neoplasms, Cervix Neoplasms","enrollment":24},{"nctId":"NCT01060501","phase":"PHASE3","title":"Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer","status":"COMPLETED","sponsor":"University of Ulm","startDate":"1992-07","conditions":"Rectal Cancer","enrollment":796},{"nctId":"NCT00591188","phase":"PHASE2","title":"Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens","status":"COMPLETED","sponsor":"Kidney Cancer Research Bureau","startDate":"2006-12","conditions":"Carcinoma, Renal Cell","enrollment":49},{"nctId":"NCT00226798","phase":"PHASE2","title":"Immunochemotherapy for Metastatic Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Rambam Health Care Campus","startDate":"2003-12","conditions":"Adenocarcinoma Clear Cell","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Interferon Alfa ; IFN、","Fluorouracil ; 5-FU"],"phase":"phase_2","status":"active","brandName":"Interferon Alfa、Fluorouracil","genericName":"Interferon Alfa、Fluorouracil","companyName":"Kansai Hepatobiliary Oncology Group","companyId":"kansai-hepatobiliary-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon alfa binds to interferon receptors on the surface of cells, leading to the activation of JAK-STAT signaling pathways which enhance antiviral and antiproliferative responses; Fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis and repair in rapidly dividing cells. Used for Hepatocellular carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}